Human Adipocyte Fatty Acid-Binding Protein (aP2) Gene Promoter-Driven Reporter Assay Discriminates Nonlipogenic Peroxisome Proliferator-Activated Receptor γ Ligands
暂无分享,去创建一个
T. Wurch | D. Junquéro | J. Patoiseau | F. Lestienne | L. Puech | A. Stennevin | E. Dupont-Passelaigue | A. Rouquette | Y. Rival | Claudie Cathala | Elisabeth Dupont-Passelaigue | D. Junquero
[1] J. Beckman,et al. Peroxisome proliferator activated receptor gamma and its activation in the treatment of insulin resistance and atherosclerosis: issues and opportunities , 2003, Current opinion in cardiology.
[2] S. Haffner,et al. Epidemic obesity and the metabolic syndrome. , 2003, Circulation.
[3] S. Grundy,et al. The metabolic syndrome: a practical guide to origins and treatment: Part II. , 2003, Circulation.
[4] S. Grundy,et al. The metabolic syndrome , 2003, The Lancet.
[5] K. Brown,et al. Effects of a PPAR&ggr; Agonist, GI262570, on Renal Filtration Fraction and Nitric Oxide Level in Conscious Rats , 2003, Journal of cardiovascular pharmacology.
[6] G. L. Coleman,et al. Mechanism and Implications of Brown Adipose Tissue Proliferation in Rats and Monkeys Treated with the Thiazolidinedione Darglitazone, a Potent Peroxisome Proliferator-Activated Receptor-γ Agonist , 2003, Journal of Pharmacology and Experimental Therapeutics.
[7] R. Evans,et al. Peroxisome-Proliferator-Activated Receptor δ Activates Fat Metabolism to Prevent Obesity , 2003, Cell.
[8] Bruce A. Johnson,et al. Distinct properties and advantages of a novel peroxisome proliferator-activated protein [gamma] selective modulator. , 2003, Molecular endocrinology.
[9] B. Spiegelman,et al. Genetic Analysis of Adipogenesis through Peroxisome Proliferator-activated Receptor γ Isoforms* , 2002, The Journal of Biological Chemistry.
[10] B. Staels,et al. Pleiotropic Actions of Peroxisome Proliferator-Activated Receptors in Lipid Metabolism and Atherosclerosis , 2002, Arteriosclerosis, thrombosis, and vascular biology.
[11] W. Wahli,et al. Peroxisome proliferator-activated receptors (PPARs): from metabolic control to epidermal wound healing. , 2002, Swiss medical weekly.
[12] P. Pauwels,et al. Pharmacological analysis of wild-type α, γ and δ subtypes of the human peroxisome proliferator-activated receptor , 2002, Naunyn-Schmiedeberg's Archives of Pharmacology.
[13] M. Matsuda,et al. Enhancement of the Aquaporin Adipose Gene Expression by a Peroxisome Proliferator-activated Receptor γ* , 2001, The Journal of Biological Chemistry.
[14] M. Matsuda,et al. PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. , 2001, Diabetes.
[15] T. Willson,et al. Adipose Tissue Resistin Expression Is Severely Suppressed in Obesity and Stimulated by Peroxisome Proliferator-activated Receptor γ Agonists* , 2001, The Journal of Biological Chemistry.
[16] S. Kliewer,et al. A selective peroxisome proliferator-activated receptor δ agonist promotes reverse cholesterol transport , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[17] Sander Kersten,et al. Roles of PPARs in health and disease , 2000, Nature.
[18] X. Shen,et al. Differential activation of peroxisome proliferator-activated receptor-gamma by troglitazone and rosiglitazone. , 2000, Diabetes.
[19] T. Willson,et al. The PPARs: from orphan receptors to drug discovery. , 2000, Journal of medicinal chemistry.
[20] J. Lehmann,et al. A peroxisome proliferator-activated receptor gamma ligand inhibits adipocyte differentiation. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[21] M. Lazar,et al. Mechanisms by which Thiazolidinediones Enhance Insulin Action , 1999, Trends in Endocrinology & Metabolism.
[22] M. Lazar,et al. A Potent Antidiabetic Thiazolidinedione with Unique Peroxisome Proliferator-activated Receptor γ-activating Properties* , 1998, The Journal of Biological Chemistry.
[23] J. Lehmann,et al. N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents. , 1998, Journal of medicinal chemistry.
[24] J. Flier,et al. Ligand-independent activation domain in the N terminus of peroxisome proliferator-activated receptor gamma (PPARgamma). Differential activity of PPARgamma1 and -2 isoforms and influence of insulin. , 1997, The Journal of biological chemistry.
[25] J. Veerkamp,et al. Assignment of the human adipocyte fatty acid-binding protein gene (FABP4) to chromosome 8q21 using somatic cell hybrid and fluorescence in situ hybridization techniques. , 1997, Genomics.
[26] J. Lehmann,et al. Peroxisome Proliferator-activated Receptors α and γ Are Activated by Indomethacin and Other Non-steroidal Anti-inflammatory Drugs* , 1997, The Journal of Biological Chemistry.
[27] M. D. Leibowitz,et al. Molecular Cloning, Expression and Characterization of Human Peroxisome Proliferator Activated Receptors γ1 and γ2 , 1996 .
[28] J. Lehmann,et al. An Antidiabetic Thiazolidinedione Is a High Affinity Ligand for Peroxisome Proliferator-activated Receptor γ (PPARγ) (*) , 1995, The Journal of Biological Chemistry.
[29] B. Spiegelman,et al. Identification of a fat cell enhancer: Analysis of requirements for adipose tissue‐specific gene expression , 1992, Journal of cellular biochemistry.
[30] A. Smith,et al. Human adipocyte lipid-binding protein: purification of the protein and cloning of its complementary DNA. , 1989, Biochemistry.
[31] J. Gordon,et al. Analysis of the tissue-specific expression, developmental regulation, and linkage relationships of a rodent gene encoding heart fatty acid binding protein. , 1987, The Journal of biological chemistry.
[32] H. Green,et al. The nucleotide sequence of three genes participating in the adipose differentiation of 3T3 cells. , 1986, The Journal of biological chemistry.
[33] H. Minuk,et al. Metabolic syndrome. , 2005, Journal of insurance medicine.
[34] C. Schöfl,et al. Postmarketing Surveillance Study of the Efficacy and Tolerability of Pioglitazone in Insulin-Resistant Patients with Type 2 Diabetes Mellitus in General Practice , 2003, Clinical drug investigation.
[35] A. Wolffe,et al. PPARgamma knockdown by engineered transcription factors: exogenous PPARgamma2 but not PPARgamma1 reactivates adipogenesis. , 2002, Genes & development.
[36] Douglas J. A. Adamson,et al. Diclofenac antagonizes peroxisome proliferator-activated receptor-γ signaling , 2002 .
[37] A. Wolffe,et al. PPARγ knockdown by engineered transcription factors: exogenous PPARγ2 but not PPARγ1 reactivates adipogenesis , 2002 .
[38] M. Jaye,et al. PPAR-α and PPAR-γ activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway , 2001, Nature Medicine.
[39] R. Evans,et al. A PPARγ-LXR-ABCA1 Pathway in Macrophages Is Involved in Cholesterol Efflux and Atherogenesis , 2001 .
[40] M. D. Leibowitz,et al. Molecular cloning, expression and characterization of human peroxisome proliferator activated receptors gamma 1 and gamma 2. , 1996, Biochemical and biophysical research communications.
[41] J. Lehmann,et al. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). , 1995, The Journal of biological chemistry.